A detailed history of Prelude Capital Management, LLC transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 11,689 shares of STRO stock, worth $21,975. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,689
Previous 11,689 -0.0%
Holding current value
$21,975
Previous $40,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.88 - $5.01 $52,704 - $91,683
-18,300 Reduced 61.02%
11,689 $40,000
Q2 2024

Aug 14, 2024

BUY
$2.92 - $5.33 $55,862 - $101,968
19,131 Added 176.19%
29,989 $87,000
Q1 2024

May 15, 2024

SELL
$3.27 - $5.65 $139,553 - $241,125
-42,677 Reduced 79.72%
10,858 $61,000
Q4 2023

Feb 14, 2024

BUY
$2.07 - $4.54 $71,622 - $157,084
34,600 Added 182.73%
53,535 $229,000
Q3 2023

Nov 14, 2023

SELL
$3.29 - $4.9 $36,969 - $55,061
-11,237 Reduced 37.24%
18,935 $65,000
Q2 2023

Aug 14, 2023

SELL
$4.25 - $5.88 $2,618 - $3,622
-616 Reduced 2.0%
30,172 $140,000
Q1 2023

May 15, 2023

BUY
$4.48 - $8.45 $51,658 - $97,436
11,531 Added 59.88%
30,788 $142,000
Q4 2022

Feb 14, 2023

BUY
$5.41 - $8.08 $104,180 - $155,596
19,257 New
19,257 $155,000
Q4 2020

Feb 16, 2021

SELL
$10.16 - $23.98 $7,112 - $16,786
-700 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$7.44 - $13.15 $2,232 - $3,945
300 Added 75.0%
700 $7,000
Q2 2020

Aug 14, 2020

BUY
$7.24 - $11.05 $724 - $1,105
100 Added 33.33%
400 $3,000
Q4 2019

Feb 14, 2020

SELL
$8.15 - $11.39 $8,247 - $11,526
-1,012 Reduced 77.13%
300 $3,000
Q3 2019

Nov 14, 2019

BUY
$7.91 - $11.76 $3,179 - $4,727
402 Added 44.18%
1,312 $12,000
Q2 2019

Aug 14, 2019

BUY
$9.69 - $12.23 $8,817 - $11,129
910 New
910 $10,000

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $98.1M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.